Insilico Medicine and Eli Lilly Announce $2.75B AI Drug Discovery Collaboration
– Drug Discovery Collaboration: Insilico Medicine, an AI-native clinical-stage biotech, has signed a massive drug discovery collaboration with pharma giant Eli Lilly.
– The Financials: The deal is structured with a highly lucrative $115M upfront payment to Insilico. With development, regulatory, and commercial milestones, the total deal value could reach $2.75 billion, plus tiered royalties on future sales.
Generative Pharma.AI Engine
Insilico isn’t just using machine learning to sort through existing chemical libraries faster. They are utilizing generative AI to design entirely novel molecules from scratch. Their proprietary Pharma.AI platform handles the process end-to-end: it identifies novel disease targets, generates the novel molecular structures to hit those targets, and predicts how those molecules will behave in human clinical trials.
Under this new agreement, Lilly is acquiring an exclusive worldwide license for potentially best-in-class, novel oral therapeutics that Insilico has already brought into preclinical development. Furthermore, the two companies will collaborate on entirely new R&D programs focused on targets specifically selected by Lilly.
Coming off its recent IPO on the Hong Kong Stock Exchange, Insilico gets the massive balance sheet and clinical muscle required to actually push its AI-designed drugs across the FDA finish line. Meanwhile, Eli Lilly gets to drastically compress its discovery timelines, replacing traditional trial-and-error with generative precision. In the hyper-competitive race to cure complex diseases, speed is the ultimate currency—and Eli Lilly just bought the fastest engine on the market.
“From its inception, Insilico Medicine has been developing deep learning for end-to-end drug discovery. By deploying frontier AI technologies that scale from biomarkers to life models, world models of human and animal life, we can identify multi-purpose targets driving multiple diseases at the same time,” said Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine. “Working with Lilly, we aim to deliver transformative therapies that treat diseases with high unmet need. This collaboration is a testament to the power of AI in tackling the most complex challenges in human health.”
